Search

Author/Creator Lovern, Mark

1. A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects. Issue 6 (20th October 2014)

Authors:
Wilfret, David A.; Walker, Jill; Voitenleitner, Christian; Baptiste‐Brown, Sharon; Lovern, Mark; Kim, Joseph; Adkison, Kimberly; Shotwell, Brad; Mathis, Amanda; Moss, Lee; Lee, Daniel; Yu, Lou; Gan, Jianjun; Spaltenstein, Andrew
Journal:
Clinical pharmacology in drug development
Issue:
Volume 3:Issue 6(2014:Nov./Dec.)
Page Start:
439
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Issue 2 (28th September 2018)

Authors:
Li, Jianguo; Lovern, Mark; Green, Michelle L.; Chiu, Joannellyn; Zhou, Diansong; Comisar, Craig; Xiong, Yuan; Hing, Jeremy; MacPherson, Merran; Wright, James G.; Riccobene, Todd; Carrothers, Timothy J.; Das, Shampa
Journal:
Clinical and translational science
Issue:
Volume 12:Issue 2(2019)
Page Start:
151
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. (19th November 2021)

Authors:
Yi, B. Alexander; Freedholm, Debra; Widener, Nancy; Wang, Xiaohui; Simard, Emilie; Cullen, Constance; Al‐Saady, Naab M.; Lepor, Norman E.; Coulter, Sara; Lovern, Mark; Bloomfield, Dan
Journal:
Journal of thrombosis and haemostasis
Issue:
Volume 20:Number 2(2022)
Page Start:
307
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older. Issue 3 (22nd November 2021)

Authors:
Franzese, Richard C.; McFadyen, Lynn; Watson, Kenny J.; Riccobene, Todd; Carrothers, Timothy J.; Vourvahis, Manoli; Chan, Phylinda L.S.; Raber, Susan; Bradley, John S.; Lovern, Mark
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 111:Issue 3(2022)
Page Start:
635
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Population Pharmacokinetic Modeling for Ceftazidime‐Avibactam Renal Dose Adjustments in Pediatric Patients 3 months and Older. Issue 1 (16th November 2022)

Authors:
Franzese, Richard; Riccobene, Todd; Carrothers, Timothy; Vourvahis, Manoli; Winter, Erica; Lovern, Mark; McFadyen, Lynn
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 113:Issue 1(2023)
Page Start:
182
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects. Issue 10 (4th July 2022)

Authors:
Han, Kelong; Baker, Mark; Lovern, Mark; Paul, Prokash; Xiong, Yuan; Patel, Parul; Moore, Katy P.; Seal, Ciara S.; Cutrell, Amy G.; D'Amico, Ronald D.; Benn, Paul D.; Landovitz, Raphael J.; Marzinke, Mark A.; Spreen, William R.; Ford, Susan L.
Other Names:
Gacia‐Bournissen Facundo guestEditor.; Rieder Michael guestEditor.
Journal:
British journal of clinical pharmacology
Issue:
Volume 88:Issue 10(2022)
Page Start:
4607
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗